Yungjin Pharm Co Ltd (003520) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.078x

Based on the latest financial reports, Yungjin Pharm Co Ltd (003520) has a cash flow conversion efficiency ratio of 0.078x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩7.00 Billion ≈ $4.74 Million USD) by net assets (₩90.02 Billion ≈ $61.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Yungjin Pharm Co Ltd (003520) balance sheet quality index to measure how much of total assets are equity-financed.

Yungjin Pharm Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Yungjin Pharm Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Yungjin Pharm Co Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.

Yungjin Pharm Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Yungjin Pharm Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Smith-Midland Corp NASDAQ:SMID	0.048x
Kss Line KO:044450	0.044x
Genic Co. Ltd KQ:123330	-0.124x
Gabelli Healthcare & WellnessRx Trust NYSE:GRX	-0.019x
UPDATER SERVICES LIMITED NSE:UDS	0.032x
Donpon Precision TWO:3290	0.001x
AGV Products Corp TW:1217	0.017x
Samjin Pharm KO:005500	-0.005x

Annual Cash Flow Conversion Efficiency for Yungjin Pharm Co Ltd (2013–2024)

The table below shows the annual cash flow conversion efficiency of Yungjin Pharm Co Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Yungjin Pharm Co Ltd (003520) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩89.80 Billion ≈ $60.86 Million	₩21.74 Billion ≈ $14.73 Million	0.242x	+312.24%
2023-12-31	₩89.63 Billion ≈ $60.74 Million	₩-10.22 Billion ≈ $-6.93 Million	-0.114x	+11.70%
2022-12-31	₩89.87 Billion ≈ $60.90 Million	₩-11.61 Billion ≈ $-7.87 Million	-0.129x	-261.92%
2021-12-31	₩104.89 Billion ≈ $71.08 Million	₩8.37 Billion ≈ $5.67 Million	0.080x	-37.03%
2020-12-31	₩114.43 Billion ≈ $77.55 Million	₩14.50 Billion ≈ $9.82 Million	0.127x	+57.98%
2019-12-31	₩115.75 Billion ≈ $78.44 Million	₩9.28 Billion ≈ $6.29 Million	0.080x	+602.43%
2018-12-31	₩111.61 Billion ≈ $75.63 Million	₩1.27 Billion ≈ $863.49K	0.011x	-56.66%
2017-12-31	₩119.65 Billion ≈ $81.08 Million	₩3.15 Billion ≈ $2.14 Million	0.026x	-10.13%
2016-12-31	₩106.17 Billion ≈ $71.95 Million	₩3.11 Billion ≈ $2.11 Million	0.029x	-66.56%
2015-12-31	₩100.42 Billion ≈ $68.06 Million	₩8.80 Billion ≈ $5.96 Million	0.088x	+42.11%
2014-12-31	₩100.79 Billion ≈ $68.30 Million	₩6.22 Billion ≈ $4.21 Million	0.062x	+6.13%
2013-12-31	₩102.45 Billion ≈ $69.43 Million	₩5.95 Billion ≈ $4.03 Million	0.058x	--

About Yungjin Pharm Co Ltd

KO:003520 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$152.08 Million

₩224.41 Billion KRW

Market Cap Rank

#17619 Global

#722 in Korea

Share Price

₩1227.00

Change (1 day)

+0.57%

52-Week Range

₩1105.00 - ₩2170.00

All Time High

₩17500.00